<DOC>
	<DOCNO>NCT01543464</DOCNO>
	<brief_summary>The aim study assess treatment IDO/Survivin peptide vaccine enhance efficacy temozolomide chemotherapy patient metastatic malignant melanoma .</brief_summary>
	<brief_title>Peptide Vaccine Temozolomide Metastatic Melanoma Patients</brief_title>
	<detailed_description>Secondarily study efficacy treatment ; investigator examine treatment IDO/Survivin peptide induce measurable cellular T-cell response vaccine give combination temozolomide treatment melanoma patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Histological verify malignant melanoma 2 . Metastatic disease ( brain metastasis allow asymptomatic ) 3 . Evaluable disease record RECIST v. 1.1 4 . Age &gt; 18 year 5 . Performance status , PS=0 , PS=1 PS=2 6 . Life expectancy &gt; 3 month 7 . Adequate bone marrow function 8 . Leucocyte count &gt; 2,5 * 109/L 9 . Granulocyte count &gt; 1,5 * 109/L 10 . Thrombocyte count &gt; 100 * 109/l 11 . Creatinine &lt; 2,5 * UNL 130 micromol/L 12 . Adequate liver function 13 . ASAT &lt; 100 U/L 14 . Bilirubin &lt; 300 U/L 15 . ShCG negative ( fertile woman ) 16 . Written inform consent 17 . Inclusion least 4 week major abdominal surgery 18 . If radiotherapy brain metastasis prior inclusion , progressive disease proven new brain MRscan inclusion 1 . Treatment immune suppressor ( ie . prednisone ) allow 2 . Other malignancy 3 year prior inclusion except benign skin lesion 3 . Severe medical condition , severe asthma , severe COL , severe heart diabetic disease 4 . Acute/Chronic infection HIV , hepatitis tuberculosis 5 . Known severe allergic reaction 6 . Former anaphylactic reaction 7 . Active autoimmune diseases 8 . Pregnant nourishing woman 9 . Psychiatric disease result noncompliance 10 . Known allergic reaction towards Montanide , Imiquimod , Temozolomide Leukine 11 . Simultaneously treatment experimental drug Patients treat chemotherapy , radiotherapy ( except locally ) immunotherapy 14 day within inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Indeolamine 2,3 dioxygenase</keyword>
	<keyword>Survivin</keyword>
	<keyword>Montanide</keyword>
	<keyword>Imiquimod</keyword>
	<keyword>GMCSF</keyword>
</DOC>